Endometrial Cancer

Adjunctive SGLT2 Inhibitors with Progestins Reduce Endometrial Cancer Risk in Benign Uterine Conditions: Insights from a Large Real-World Study

A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer